OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Clinical Oncology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)

Article	Citations
Nirogacestat effective in desmoid tumours	1659
Immunotherapy approaches for malignant pleural mesothelioma	944
BRAF-mutant ctDNA predicts outcomes	864
Enfortumab vedotin is safe and effective	750
Initial pirtobrutinib data show promise	637
HSCT prolongs remission of high-risk CTCLs	630
Whole-genome sequencing for myeloid disease: one assay to stratify them all?	628
Combination improves salvage outcomes	612
New treatment strategies for advanced-stage gastrointestinal stromal tumours	611
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care	536
Practicing on the edge of oncology: when standard of care feels uncomfortable	471
Tabelecleucel is effective in EBV-positive lymphoproliferative disease	468
Cerebrospinal fluid liquid biopsies for medulloblastoma	455
Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe	446
New insights from recurrence score	431
Promising OS with oncolytic virotherapy	428
Adjuvant pembrolizumab improves overall survival in patients with RCC	417
HPV-associated oropharyngeal cancer — discussion points	383
Copanlisib safe and active in combination	381
Cemiplimab is a new option in BCC	377
Adjuvant pembrolizumab shows promise	345
BrECADD raises the bar in classical Hodgkin lymphoma	331
NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer	325
The immune landscape of common CNS malignancies: implications for immunotherapy	287
Nano-omics: nanotechnology-based multidimensional harvesting of the blood-circulating cancerome	286

Should the control arms of randomized trials have an expiry date?	281
Adjuvant olaparib — should all patients with breast cancer have genetic testing?	277
Capivasertib delays disease progression	265
HSP90 inhibition improves GIST survival	252
KEYNOTE-355 — OS benefit now reported	242
Tasadenoturev active in DIPG	242
Finding the Goldilocks zone in neoadjuvant radioimmunotherapy	220
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer	215
Biobanking in radiotherapy trials — a challenge to the clinical research community	215
Nucleic acid-based drugs for patients with solid tumours	214
From ASCO 2023	213
‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent	210
Abemaciclib crowned in monarchE	204
GPRC5D-CAR T cells active in MM	200
Dabrafenib–trametinib moves to the first line in low-grade glioma	199
Efficacy of TILs confirmed	198
Promise with co-administration of CAR T cells	195
Sotorasib dosing and incremental cost ineffectiveness — implications and lessons for stakeholders	189
A new standard of care for advanced-stage urothelial carcinoma	179
Pegargiminase improves outcomes in nonepithelioid MPM	178
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC	177
CAR T cells in multiple myeloma: lessons learned	176
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC	174
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes	174
Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks	165
Beneficial autoimmunity improves cancer prognosis	162
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm	160
The clinical development of antibody–drug conjugates — lessons from leukaemia	158
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines	156
Gut microbes as biomarkers of ICI response — sharpening the focus	149
Broadening horizons: the role of ferroptosis in cancer	149
Liquid biopsy enters the clinic — implementation issues and future challenges	149
Functional precision oncology using patient-derived assays: bridging genotype and phenotype	143
Applications of cell therapy in the treatment of virus-associated cancers	142
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma	134
Is NETTER-2 a practice-changing trial?	129
A new era for glioma therapy — targeting mutant IDH	123
Novel ICI–TKI combination improves HCC outcomes	121
Uncovering adagrasib resistance	120
Lack of benefit from extended lymphadenectomy in muscle-invasive bladder cancer	119
Reply to ‘NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3’	117
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime	116
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials	116
Targeting cuproplasia and cuproptosis in cancer	113
From little subclones grow mighty oaks	110
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?	100
Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy	100
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety	99
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma	98
Gut microbiota in colorectal cancer development and therapy	91

Nasopharyngeal carcinoma: an evolving paradigm	87
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination	86
Molecular tumour boards — current and future considerations for precision oncology	86
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma	84
Current understanding and management of CAR T cell-associated toxicities	82
Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood	81
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer	80
Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer	78
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management	72
Anaplastic glioma: benefit of temozolomide clarified	71
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis	70
Oncology approvals in 2020: a year of firsts in the midst of a pandemic	70
From ASCO 2022	70
Exploiting bacteria for cancer immunotherapy	67
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies	66
The MYC oncogene — the grand orchestrator of cancer growth and immune evasion	64
The emerging roles of circRNAs in cancer and oncology	61
Exploring the next generation of antibody–drug conjugates	60
The current state of the art and future trends in RAS-targeted cancer therapies	58
Dostarlimab effective in dMMR LARC	57
Belzutifan is active in VHL-related cancers	56
Belzutifan has potential in RCC	56
CAR T cells show promise in mesothelioma	55
Zolbetuximab moves into the SPOTLIGHT	55
Addition of sintilimab to standard therapy improves event-free survival	52
Predicting tumour origin with cytology-based deep learning: hype or hope?	50
A triple dose of optimism: an initial foray into triplet therapy in metastatic renal cell carcinoma	45
Pembrolizumab tunes up chemotherapy in cervical cancer	43
A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise	41
Brentuximab vedotin improves outcomes	41
KN046 shows tolerability and activity in TNBC	40
Synergy of EphB2 and PD-1 blockade	39
Mortality is similar with active monitoring	39
Neoadjuvant pembrolizumab improves outcomes	39
Sacituzumab govitecan is safe and effective	38
Medulloblastoma: prognostic subtypes revealed	38
SUNLIGHT illuminates the activity of bevacizumab	38
ROAR brings in a new histology-agnostic approval for rare cancers	37
Neoadjuvant pembrolizumab shows promise in MSI-H/dMMR solid tumours	35
T-DXd improves PFS versus T-DM1	35
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence	35
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs	34
Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes	33
Harnessing cytokines and chemokines for cancer therapy	33
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management	32
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed	28
Humanized mouse models for immuno-oncology research	27
Optimizing the safety of antibody–drug conjugates for patients with solid tumours	27
Contrasting results with second-line CAR T cells in large B cell lymphoma	26
Digital symptom assessment tools: the next frontier in financial toxicity screening	24
Navigating approval pathways for immunotherapy in NSCLC: should criteria be revised?	24
Ensuring completeness and timeliness of cancer treatment guidelines	24
CAR T cells show activity	24
Cytoreductive surgery effective after relapse	24
Benefit with adjuvant metronomic capecitabine in NPC	23
Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma	23